RTP Mobile Logo
Year in Review: Clinical Investigator Perspectives on the Most Relevant New Data Sets and Advances in Hepatobiliary and Pancreatic Cancers (Webinar Audio Proceedings)
Released May 2022

Featuring perspectives from Drs Tanios Bekaii-Saab and Philip Philip. Published May 5, 2022. (Webinar Audio Proceedings)

CE Information and Faculty Disclosures

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of hepatobiliary and pancreatic cancers.

    LEARNING OBJECTIVES

    • Consider age, performance status, degree of liver function and other clinical and logistical factors in the selection of first- and later-line therapy for patients with unresectable or metastatic hepatocellular carcinoma (HCC).
    • Appreciate available and emerging Phase III data with novel first-line treatment strategies for unresectable or metastatic HCC and other hepatobiliary cancers, and discuss how these approaches can be optimally integrated into the current and future clinical care of patients.
    • Develop an understanding of available clinical trial findings with isocitrate dehydrogenase 1 (IDH1) inhibitors for patients with advanced cholangiocarcinoma and an IDH1 mutation, and appropriately identify individuals for whom this novel strategy is warranted.
    • Assess key data sets supporting the use of fibroblast growth factor receptor (FGFR) inhibitors for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement, and consider how these agents can be appropriately and safely integrated into clinical management algorithms.
    • Recall clinical trial data with approved and investigational systemic interventions for localized, locally advanced or metastatic pancreatic adenocarcinoma, and establish an evidence-based approach to therapeutic selection for patients.
    • Evaluate available and emerging data with investigational agents and strategies currently in clinical testing for HCC, pancreatic cancer and hepatobiliary cancers, and appropriately refer eligible patients for trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    CME credit is no longer available for this issue

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component.
    CME credit is no longer available for this issue

    Video Program: This CME activity consists of a video component.
    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Tanios Bekaii-Saab, MD
    Professor, Mayo Clinic College of Medicine and Science
    Program Leader, Gastrointestinal Cancer
    Mayo Clinic Cancer Center
    Consultant, Mayo Clinic in Arizona
    Chair, ACCRU Research Consortium
    Phoenix, Arizona

    Consulting Agreements (to Institution): Arcus Biosciences, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Pfizer Inc, Seagen Inc; Consulting Agreements (to Self): AbbVie Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, Exact Sciences, Foundation Medicine, Illumina, Janssen Biotech Inc, Kanaph Therapeutics, MJH Life Sciences, Natera Inc, Swedish Orphan Biovitrum AB, Stemline Therapeutics Inc, Treos Bio; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, FibroGen Inc, Merck, Pancreatic Cancer Action Network, Suzhou Kintor; Inventions/Patents: WO/2018/183488 licensed to Imugene, WO/2019/055687 licensed to Recursion; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merus BV, Mirati Therapeutics, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Scientific Advisory Board: Immuneering Corporation, Imugene, Replimune, Sun Biopharma, Xilis.

    Philip A Philip, MD, PhD, FRCP
    Professor of Oncology and Pharmacology
    Leader, GI and Neuroendocrine Oncology
    Henry Ford Cancer Institute
    Wayne State University
    Detroit, Michigan

    No relevant conflicts of interest to disclose.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Exelixis Inc and Novocure Inc.

    Release date: May 2022
    Expiration date: May 2023

Acknowledge and close

Watch video
(WIFI is recommended for best performance):